Search
Parabilis Medicines Ord Shs
PBLSAdd to Watchlist
33.310USD
-4.860-12.73%
Close 09-22 16:00（ET）
3.88BMarket Cap
0.00P/E TTM
PBLS Analyst Recommendation Trends
In the current month, PBLS has received 2 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. PBLS average Analyst price target in the last month is 41.750.
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
2026-02
3
3
0
0
0
0
0
0
2
2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
5
5
0
0
0
0
0
0
Financial Forecasting
Based on analysts' estimates, PBLS EPS is projected to reach -0.363 in FY2026Q3, following reported EPS of -0.542 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
--
--
0.08
-0.36
-0.38
Actual
-1.58
-0.60
-0.54
--
--
Surprise
--
--
-777.57%
--
--
FAQs
What is Parabilis Medicines Ord Shs's expected revenue for the next quarter?
Parabilis Medicines Ord Shs's expected revenue is 333.33K.
What is the analyst rating for Parabilis Medicines Ord Shs?
Based on the ratings of Parabilis Medicines Ord Shs's stock from 5 analysts, most analysts support a STRONG BUY trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as STRONG BUY. Please note that this is not trading advice. You still need to conduct your own analysis.